Skip to main content
. 2018 Feb 1;38(9):998–1010. doi: 10.1093/asj/sjy008

Figure 3.

Figure 3.

Percentage of patients achieving a ≥1-grade improvement in submental fat (SMF) from baseline based on clinician assessment via the validated Clinician-Reported SMF Rating Scale (CR-SMFRS [CR-1 response]), patient assessment via the validated Patient-Reported SMF Rating Scale (PR-SMFRS [PR-1 response]), and both clinician and patient assessment (via both the CR-SMFRS and PR-SMFRS [composite CR-1/PR-1 response]) at 12 weeks after last treatment. P < 0.001 for all comparisons between ATX-101 and placebo treatment.